Please ensure Javascript is enabled for purposes of website accessibility

How This Big Pharma Is Staging a Big Comeback

By Dave Williamson - Apr 23, 2013 at 7:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can Bristol-Myers go from also-ran to the eventual hep-C champ?

It was a big day for investors watching the race to create the next generation of hepatitis-C drug cocktails. Most of the major players released data for the European Association for the Study of the Liver conference today.

In the following video segment, health-care analyst David Williamson explains why former front-runner Bristol-Myers Squibb may have returned from the wilderness of a big drug failure to launch a second effort at claiming the crown for treating this disease. Watch and find out how Bristol matches up with its two biggest competitors, Gilead and AbbVie. Both have treatments in phase 3 trials, and Gilead recently submitted an application for approval of its cornerstone drug sofosbuvir earlier in the month. Provided no hiccups, Gilead should be able to commercialize the drug within a year, if the FDA sticks to its first-quarter 2014 deadline.

Editor's note: This video incorrectly states that Gilead's drug sofosbuvir would be available commercially by the end of the year. Given the FDA's timeline, if approved, a 2014 launch is more likely.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.70 (0.67%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.